While Cipla paid Rs 29 crore for Okasa’s facility in Goa, it bought another plant, owned by Okasa Pharma, located in Satara for Rs 71.93 cr...

Studies and research proposals include dissemination of best practices of biodiversity conservation, monitoring of glaciers receding, clima...

Among total 18 CDBRs of the country, only Spiti area of Himachal Pradesh was declared "cold desert biosphere reserve" in 2009.

Biotechnology major Biocon today said it is looking for partners to develop and market its novel biologic drug Itolizumab

The company had received marketing authorisation for Itolizumab from the Drugs Controller General of India (DCGI) in January, 2013.

Biocon logged a modest performance for the quarter ended December with net sales growth of 23% to Rs 634.2 crore and operating profit growt...

The company’s improved performance over the last four quarters is a testimony to the fact that these changes are paying off.

Cipla’s latest move to grow through acquisitions comes at a time when the company has been growing at lower than the industry growth rate f...

The drug maker will acquire 40% in Goa's Mab Pharm & 25% in Shanghai's Bio Mabs.